News & Events

26/07/2021

Fidia announces the FDA Orphan Drug designation for ONCOFID for the treatment of malignant mesothelioma, the cancer caused by exposure to asbestos

Preclinical studies are underway to complete the pharmaco-toxicological profile, with the aim of submitting the authorisation dossier for human studies to the regulatory authorities by 2022.

Abano Terme (PD), July 26th, 2021 - Fidia Farmaceutici, an Italian company world leader in the research, development, formulation and commercialization of hyaluronic acid-based products, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation for ONCOFID-P for…
29/03/2021

V International School of the ARTROMASTER Association

On March 19-20th, the V International School of the ARTROMASTER Association took place in Kazan.More than 200 traumatologists from Russian cities and other countries attended the event, in order to discuss new tendencies of treatment and diagnosis for trauma patients. The products of Fidia Pharma, a…
23/03/2021

Fidia signed a binding agreement with Sanofi for the acquisition of a Sanofi portfolio of anti-inflammatory drugs

The concluded agreement is the result of a selective competitive process launched in 2020, which led Sanofi to choose Fidia among the various participating companies.

Based on this recent operation, the company has strengthened its presence in the prescription drug market, in addition to further expanding its range of products and specialities, thus consolidating its leadership in the Joint Care area and bolstering its business in Dermatology. – Investment in…
06/05/2020

Fidia's measures and initiatives in response to the COVID-19 emergency

The company has undertaken extensive safety measures for its employees straight after the outbreak, while ensuring continuity of operations and production

Abano Terme (PD), May 5th 2020 – Fidia, Italian multinational company, with R&D, manufacturing, marketing and sales capabilities, and an extensive product portfolio mainly based on hyaluronic acid, is deeply committed to providing all the necessary support in response to the current situation with…
27/04/2020

COVID-19: communication to Partners, Customers and Suppliers

Health and safety, a top priority for Fidia

According to Fidia Farmaceutici S.p.A mission and policy, health and safety of people, and of course of our employees, are absolute priority.This is why we decided to reduce potential risks, asking our colleagues, partners, visitors, ecc… to work remotely as much as possible, as well as to strictly…
17/07/2019

Fidia presents New Data on HYMOVIS® effects on Cartilage Volume and Type II Collagen Turnover at Osteoarthritis Research Society International (OARSI) World Congress

Announcement title: "Hyaluronan Derivative Hymovis® Increases Cartilage Volume and Type II Collagen Turnover in Osteoarthritis Knee: Data from MOKHA (MRI, BiOmarkers, Knee, Hymovis®, OsteoArthritis) Study"

Press release will be translated into Russian and published
25/09/2017

FIDIA PHARMA GROUP LAUNCHES BRAND NEW HYMOVIS WEBSITE

Let's move, with Hymovis!

We are pleased to announce the release of Fidia Pharma Group's new www.hymovis.net website, designed with a user-friendly navigation, and updated with the latest information on the product. Our objective is to provide our international visitors with an easier way to learn about Hymovis and to…
19/07/2017

FIDIA FARMACEUTICI S.P.A. LEADS EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET

Global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021

“Fidia Farmaceutici has invested in research and development of hyaluronic acid-based products for more than 70 years. Today, Fidia is growing its product portfolio with new, innovative solutions to meet challenges in the field of osteoarthritis using science, our legacy and our drive.”

PARSIPPANY, N.J.--(BUSINESS WIRE)--Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA Inc., are projecting continued growth in 2017. The global viscosupplementation market is…
17/03/2017

SLEEP DISORDERS MAY AFFECT HEALTH, PERFORMANCE AT WORK AND QUALITY OF LIFE

An estimated 9 million people in Italy suffer from sleep disorders, that partially contribute to poorer work performance, general health and quality of life.

Management of sleep disorders may result in significant improvement of general health. The first step is talk to the primary care provider.

Social media use is rapidly increasing, as well as daytime and bedtime use of computers, including devices such as smartphones, tablets and laptops. Work, stress, menopause, advancing age or a variety of underlying medical conditions affecting the general population, may be responsible for those…
28/02/2017

FIDIA PHARMA GROUP EXPECTED TO BE A KEY PLAYER IN THE OPHTHALMIC SECTOR

The Company is finalizing the acquisition of Italian Sooft/Oox Group

The Group is positioned among the top four companies in this market segment, and is engaged in the development of products for all major eye diseases.

As announced at the end of 2016, Fidia has finalized the first step to the successful acquisition of the majority stake in the Sooft/Oox Group, through a legally binding agreement that will be executed over the next few weeks. Sooft/Oox is an Italian group active in the ophthalmic sector, with a…

Fidia
Farmaceutici S.p.A.
Website

Find out our Corporate Website:

Go to the website

Other product websites

Direct link to:

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Russia product portfolio focalizes primarily on joint healthcare.

Fidia Pharma Russia is focused on providing consumers with innovative products that offer quality, safety and performance.